GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Operating Margin %

InnoCare Pharma (FRA:33C) Operating Margin % : -130.92% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. InnoCare Pharma's Operating Income for the three months ended in Sep. 2023 was €-26.86 Mil. InnoCare Pharma's Revenue for the three months ended in Sep. 2023 was €20.52 Mil. Therefore, InnoCare Pharma's Operating Margin % for the quarter that ended in Sep. 2023 was -130.92%.

Good Sign:

InnoCare Pharma Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for InnoCare Pharma's Operating Margin % or its related term are showing as below:

FRA:33C' s Operating Margin % Range Over the Past 10 Years
Min: -65634.71   Med: -14642.29   Max: -15.94
Current: -94.92


FRA:33C's Operating Margin % is ranked better than
56.14% of 1026 companies
in the Biotechnology industry
Industry Median: -175.525 vs FRA:33C: -94.92

InnoCare Pharma's 5-Year Average Operating Margin % Growth Rate was 76.10% per year.

InnoCare Pharma's Operating Income for the three months ended in Sep. 2023 was €-26.86 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was €-44.14 Mil.


InnoCare Pharma Operating Margin % Historical Data

The historical data trend for InnoCare Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Operating Margin % Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -20,100.63 -36,353.80 -15.94 -116.91 -87.97

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -113.36 -99.54 - -130.92 -66.87

Competitive Comparison of InnoCare Pharma's Operating Margin %

For the Biotechnology subindustry, InnoCare Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Operating Margin % falls into.



InnoCare Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

InnoCare Pharma's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-99 / 84.683
=-116.91 %

InnoCare Pharma's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-26.864 / 20.519
=-130.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCare Pharma  (FRA:33C) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


InnoCare Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (FRA:33C) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines